Jade Biosciences, Inc. (JBIO)
D
Pipeline Grade
Financial Position (from SEC Filings)
$180.9M
Cash & Equivalents
$24.1M
Quarterly Burn Rate
23 mo
Est. Cash Runway
$1,275M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-10-01 | Phase1 Readout | — |
| 2027-05-01 | Phase1 Readout | — |
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07541287 | A Study of JADE101 in Participants With Immunoglobulin A Nephropathy | PHASE2 | Recruiting | 30 |
| NCT07533955 | A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis | PHASE1 | Recruiting | 36 |
| NCT07059312 | A Phase 1 Study of JADE101 in Healthy Participants | PHASE1 | Active Not Recruiting | 32 |
| NCT07525947 | A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants | PHASE1 | Recruiting | 40 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-01 | 8-K | Jade Biosciences, Inc. (JBIO) (CIK 0001798749) - EX-99.1 | EDGAR |